SCHEMBL5486659

SCHEMBL5486659

CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)Nc3c2nnc(Cl)c3C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
LMNA P02545 4/20 0.38
POLB P06746 2/20 0.33
PKM P14618 1/20 0.33
GLA P06280 2/20 0.32
GAA P10253 2/20 0.32
HTT P42858 2/20 0.32
KDM4E B2RXH2 2/20 0.32
CNR1 P21554 1/20 0.32
GPR35 Q9HC97 1/20 0.32
GPR55 Q9Y2T6 1/20 0.32
ELANE P08246 1/20 0.32
KIF11 P52732 1/20 0.32
HSD17B10 Q99714 2/20 0.31
RAB9A P51151 4/20 0.31
KMT2A Q03164 3/20 0.31
ALDH1A1 P00352 2/20 0.31
MEN1 O00255 2/20 0.31
NPC1 O15118 2/20 0.31
HSP90AA1 P07900 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5481746 0.82 CNR1 (0.48) PKMHTTCNR1GPR35GPR55
SCHEMBL5482053 0.76 MAPT (0.56) MAPTLMNAPOLBPKMGLA
SCHEMBL5479020 0.74 MAPT (0.48) MAPTLMNAPOLBPKMGLA
SCHEMBL5482056 0.73 MAPT (0.47) MAPTLMNAPOLBPKMGLA
SCHEMBL5480261 0.72 MAPT (0.46) MAPTLMNAPOLBPKMGLA
SCHEMBL5480288 0.71 MAPT (0.48) MAPTLMNAPOLBPKMGLA
SCHEMBL5474601 0.70 MAPT (0.49) MAPTLMNAGLAHTTCNR1
SCHEMBL5480016 0.69 MAPT (0.48) MAPTLMNAPOLBGLAHTT
SCHEMBL5483571 0.68 MAPT (0.56) MAPTLMNAPOLBPKMGLA
SCHEMBL5488442 0.68 MAPT (0.47) MAPTGLAHTTCNR1GPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 MAPT 1785/4885LMNA 3104/4885POLB 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.